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We have previously demonstrated that in non-squamous
non-small cell lung cancer (nsNSCLC) cells expressing
relatively high levels of the glucocorticoid receptor (GR),
dexamethasone (Dex) induces reversible G1 arrest that
is virtually complete by 72h of Dex treatment. We have
also shown that this effect of Dex protects the cells from
the cytotoxicity of pemetrexed, a mainstay chemo-
therapy in advanced nsNSCLC that entails co-adminis-
tration of Dex. Further, induction of G1 arrest by Dex
was conﬁrmed by FLT-PET imaging of tumor lesions in
patients treated with Dex for 24h. Here we report the
effects of long-term treatment of nsNSCLC cells with Dex.
The nsNSCLC cell line models included A549 (GRhi),
H292 (GRhi), H1650 (GRlo) and H1299 (GRlo) cells as
well as clonal recombinant H1299 cells overexpressing
GR. In only the GRhi cells, Dex caused an increase in p21
peaking on Day 7 and declining by Day 14. The cells
retained proliferation potential on Day 3 as measured by
colony formation. By Day 7 of Dex treatment, the GRhi
cells but not the GRlo cells exhibited a senescence
phenotype, marked by cytosolic beta-galactosidase ac-
tivity and increases in p16 and p15 at the mRNA and
protein levels as well as signiﬁcant increases in cell size.
The GRhi cells displayed a progressively decreasing
ability to form colonies until 6 weeks of Dex treatment.
The extent of this loss of proliferation potential
was related to relative GR expression levels among the
Dex-sensitive cells. When mice bearing xenografts of
H1299 (GRlo) or isogenic recombinant H1299-GR (GRhi)
cells were implanted with slow release Dex pellets, tu-
mor growth was inhibited only in the H1299-GR cells.
Evaluation of a tissue microarray as well as a cDNA array
from clinical nsNSCLC tumors showed that about 20
percent of the tumors showed uniform expression of GRthat were comparable to the levels required for Dex to
induce senescence in vitro or to inhibit tumor growth in
vivo. The results suggest that long-term administration
of Dex could serve as an additional treatment option for
a small cohort of lung adenocarcinoma patients that
harbor uniform high levels of GR in their tumor lesions.
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Background: X-396 is a novel, potent anaplastic lym-
phoma kinase (ALK) small molecule tyrosine kinase in-
hibitor (TKI) with additional activity against MET, ABL,
Axl, EPHA2, LTK, ROS1 and SLK. It has demonstrated
signiﬁcant anti-tumor activity in both ALK TKI-naive and
crizotinib-resistant models of ALK fusion-positive NSCLC.
Methods: In this multicenter phase I/II study, patients
(pts) with advanced solid tumors were enrolled in the
phase I dose escalation portion of the study and given
X-396 on a continuous 28-day schedule (NCT01625234).
Doses from 25 up to 250 mg once daily were evaluated
and 225 mg was selected for further evaluation in the
phase II expansion. Patients in this phase were required
to have ALKþ NSCLC and measurable disease. Cohorts
included pts who were 1) ALK TKI-naïve, 2) pts who
progressed on prior crizotinib and had not received a 2nd
generation ALK TKI, 3) pts who progressed on a 2nd
generation ALK TKI (may also have received crizotinib),
4) pts with central nervous system (CNS) metastases, and
5) pts with leptomeningeal disease. All pts were assessed
for adverse events (AEs) using CTCAE version 4.03,
response to therapy was assessed using RECIST 1.1.
Results: As of the October 15, 2015 data cutoff, 53 pts
(29 men, 24 women) have been enrolled. Median age is
56 (20-79) years, the majority of patients had ECOG
performance status 1 (68%). The most common drug-
related AEs included rash (47%), nausea (28%),
